Has Tarek Hassan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $460,174 in general payments to Tarek Hassan, MD across 248 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Tarek Hassan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Tarek Hassan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Tarek Hassan, MD

Retina Specialist · Royal Oak, MINPI 1154367902

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $302,376 of the $460,174 with a category attached, or 65.7%. Oculus Surgical Inc. accounts for 61.2% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $95,891, 3.0 times the $31,685 reported in 2019. Among retina specialist clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$460,174in general payments, 2019–2025

Across 248 payments — averaging $1855.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Oculus Surgical Inc.$282K
AbbVie$55K
Novartis Pharma AG$44K
Katalyst Surgical, LLC$21K
Beaver-visitec International, Inc.$16K
Alcon$13K
plus $30K from 19 others

$342,313in research payments, 2019–2025

Across 9 payments — averaging $38,035 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$342K

What the payments were for

Royalty or licence$302,37666%
Consulting fees$130,42528%
Speaking & faculty fees$10,0752%
Travel & lodging$2,7071%
Food & beverage$14,5633%
Entertainment$290%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Oculus Surgical Inc.	24	$281,736
AbbVie(2 entities)	74	$54,729
Novartis Pharma AG	8	$43,538
Katalyst Surgical, LLC	9	$21,087
Beaver-visitec International, Inc.	4	$16,023
Alcon	16	$12,984
Alimera Sciences, Inc.	18	$7,093
Novartis	10	$7,087
Coherus Oncology, Inc.	2	$4,000
Apellis Pharmaceuticals, Inc.	6	$3,197
Alcon Research LLC	2	$2,400
Bausch & Lomb, A Division Of Bausch Health US, LLC	7	$1,931
Eyepoint US, Inc.	2	$1,525
Regeneron Healthcare Solutions, Inc.	32	$988
Ocular Therapeutix, Inc.	6	$387
Genentech USA, Inc.	11	$313
ANI Pharmaceuticals, Inc.	2	$220
Genentech, Inc.	2	$215
Johnson & Johnson	2	$156
Bausch & Lomb Americas Inc.	1	$152
Iridex Corporation	2	$149
Astellas Pharma US Inc	5	$144
Notal Vision, Inc.	1	$75
Biogen	1	$23
Regeneron	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Hassan Tornambe Lens$239,982
SUPER VIEW Lens, Disposable Contact, Hassan-Tornambe$41,307
BLZ_BEOVU_OPHTHALMOLOGY$30,369
OZURDEX$25,011
BEOVU$20,041
25ga Stiff Slim DEX Hassan Forceps$12,244
Unity$9,318
Iluvien$6,863
Cimerli$4,000
YUTIQ$2,967
EYP-1901$1,525
XIPERE$1,500
NGENUITY$1,217
STELLARIS PC$285
PURIFIED CORTROPHIN GEL$189
STELLARIS$152
AcrySof IQ PanOptix$150
DEXTENZA$129
SUSVIMO$125
EYLEA HD$125

How this compares

$460,174 in reported general payments places this provider in the 95th percentile of 52 retina specialist providers in Michigan.

See all retina specialist providers in Michigan →

Medicare billing

Part B allowed, 2024

$2,324,439

Medicare patients

450

Services billed

15,207

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	58	$3,641
Ketorolac Tromethamine	92	$1,988

Paid to pharmacies, not to this prescriber.

Other retina specialist in Royal Oak

Jeremy WolfeRoyal Oak$809K
Lisa FaiaRoyal Oak$520K
Sandeep RandhawaRoyal Oak$94K
Kimberly DrenserRoyal Oak$79K
Adam WeinerRoyal Oak$31K
Michael TreseRoyal Oak$26K
Antonio CaponeRoyal Oak$20K
Ramon LeeRoyal Oak$19K
Jong ParkRoyal Oak$12K
Tianyu LiuRoyal Oak$5K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →